![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Daiichi Sankyo’s Enhertu Gets Accelerated Approval for Breast Cancer
Daiichi Sankyo’s Enhertu Gets Accelerated Approval for Breast Cancer
December 31, 2019
Daiichi Sankyo’s Enhertu (fam-trastuzumab deruxtecan-nxki) has received the FDA’s accelerated approval status for treating adults with HER2-positive breast cancer.
The agency approved the drug for patients with unresectable or metastatic HER2-positive breast cancer who have already received two or more anti-HER2-based regimens.
The approval stemmed from a clinical trial of 184 female patients, 60.3 percent of which experienced some tumor shrinkage.
Upcoming Events
-
21Oct